Related Experiment Video
Updated: Apr 27, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.1K
Age as a prognostic factor in anaplastic thyroid cancer
Vladan Zivaljevic1, Katarina Tausanovic2, Ivan Paunovic1
1Center for Endocrine Surgery, Clinical Center of Serbia, 11000 Belgrade, Serbia ; School of Medicine, Belgrade University, 11000 Belgrade, Serbia.
International Journal of Endocrinology
|July 16, 2014
Summary
Age is a significant factor influencing survival in anaplastic thyroid cancer (ATC). Younger patients, particularly those under 50, experience better outcomes, highlighting age as an independent prognostic indicator for favorable survival.
Area of Science:
- Oncology
- Endocrinology
- Medical Statistics
Background:
- Anaplastic thyroid cancer (ATC) is characterized by extremely poor patient survival.
- Identifying prognostic factors is crucial for managing this aggressive malignancy.
Purpose of the Study:
- To investigate the prognostic significance of patient age in anaplastic thyroid cancer survival.
- To determine if age is an independent predictor of survival in ATC patients.
Main Methods:
- Analysis of data from 150 anaplastic thyroid cancer patients diagnosed between 1995 and 2006.
- Kaplan-Meier method and log-rank test for overall survival assessment.
- Univariate and multivariate Cox regression analyses to identify prognostic factors.
Main Results:
- Age was significantly associated with longer survival in univariate analysis.
- Multivariate analysis identified patient age (P=0.023) and surgery (P=0.000) as independent prognostic factors for favorable survival.
- Youngest patient was 35, oldest was 89; younger age correlated with better outcomes.
Conclusions:
- Patient age is an independent prognostic factor associated with survival in anaplastic thyroid cancer.
- Anaplastic thyroid cancer demonstrates the best prognosis in patients younger than 50 years.
Related Concept Videos
01:27Hyperthyroidism II: Pathophysiology
25
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
25
01:24Graves Disease II: Pathophysiology
15
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
15
01:28Graves' Disease I: Introduction
17
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
17
01:25Hyperthyroidism I: Introduction
25
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
25
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81